Safety and Drug Utilization Profile of Varenicline as Used in General Practice in England: Interim Results from a Prescription-Event Monitoring Study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background Varenicline tartrate (Champix), a new smoking cessation medicine, was launched in the UK in December 2006. Varenicline is a highly selective partial agonist of the alpha(4)beta(2) nicotinic acetylcholine receptor (alpha(4)beta(2) receptor). The partial agonistic binding leads to alleviation of symptoms of craving and withdrawal, and simultaneously prevents nicotine from binding to the alpha(4)beta(2) receptor thereby causing reduction in the rewarding and reinforcing effects of smoking. Regulatory concerns have arisen about psychiatric events associated with varenicline, including depression, suicidal ideation and changes in behaviour/emotion.Aim To present the interim results of an ongoing study by the Drug Safety Research Unit (DSRU) monitoring the safety of varenicline.Methods The observational cohort study is being conducted to study the postmarketing safety of varenicline, using modified prescription-event monitoring (PEM) methodology. Patients are identified from dispensed prescriptions issued by general practitioners (GPs) from December 2006. Demographic, clinical event (during the course and 1 month after stopping varenicline, reasons for discontinuing and suspected adverse drug reactions [ADRs] to varenicline) and drug utilization data are collected from detailed study-specific questionnaires posted to GPs at least 4 months after the date of first prescription for each patient. Event incidence densities (IDs; number of first reports of an event/1000 patient-months of exposure) are calculated.Results The interim cohort comprises 2,682 patients: median age 47 years (interquartile range [IQR] 38-56), 60.7% females (n = 1627). Nausea/vomiting was the most frequent clinical reason for stopping varenicline (n = 91; 35.3% of clinical reasons) and the most frequently reported suspected ADR to varenicline (n = 60, 50.9% of patients for whom an ADR was reported). The most frequently reported psychiatric events (causality not implied) during treatment included (n; % of cohort): sleep disorder (43; 1.6%), anxiety (33; 1.2%), depression (29; 1.1%), abnormal dreams (26; 1.0%) and mood change (17; 0.6%). Two cases of attempted suicide were reported during treatment with varenicline (one patient took an overdose of a benzodiazepine with alcohol, the other slashed their wrist). Both these patients had previous history of psychiatric illness and precipitating factors for the event.Conclusion This study reflects 'real life' use of varenicline. Nausea/vomiting - the event most frequently reported as an ADR and as reason for stopping treatment - is listed in the UK Summary of Product Characteristics (SPC). The most frequently reported psychiatric events are listed in the UK SPC. All patients with suicidal events either had a past medical history of psychiatric illness prior to starting varenicline and/or a precipitating factor for the event. Clinicians should closely monitor patients with pre-existing psychiatric illness who are taking varenicline. Further evaluation of events of interest including psychiatric events is ongoing. Results presented are expected to change as the cohort size increases. Results of this study should be taken into account together with other clinical and pharmacoepidemiological studies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the monitoring study by Kasliwali et al.46, the most frequently reported psychiatric events during treatment included (n;% of cohort) sleep disorder (43; 1.6%), anxiety (33; 1.2%), depression (29; 1.1%), abnormal dreams (26; 1.0%), and mood change (17; 0.6%).”
From Are smoking cessation treatments associated with suicidality risk? An overview (2016) · cites this paper as [46]
Citations
Cites
(1920) · British Journal of Ophthalmology · doi:10.1136/bjo.4.1.25 · Cited by 1,606
Exacerbation of Schizophrenia by Varenicline
Freedman, R. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07020326 · Cited by 191
Varenicline-Induced Manic Episode in a Patient With Bipolar Disorder
Kohen, I., & Kremen, N. J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010173 · Cited by 126 · cited 1×
“These include exacerbation of depression in a patient with history of recurrent major depressive disorder, previously stable on fluoxetine;([13]) psychotic relapse in a patient with schizophrenia;([14]) a manic episode in a patient with a history of bipolar disorder, previously stable on valproic acid;([15])”
BackgroundVarenicline-Induced Mixed Mood and Psychotic Episode in a Patient with a Past History of Depression
Pumariega, A. J., Nelson, R., & Rotenberg, L. (2008) · CNS Spectrums · doi:10.1017/s1092852900016746 · Cited by 55 · cited 1×
“and mixed mood and psychotic episode in a patient with a past history of depression.([16]) Exacerbation of psychiatric illness occurred as early as the first week of treatment with varenicline in two of the patients.”
BackgroundLayton, D., & Shakir, S. (2012) · Pharmacoepidemiology · doi:10.1002/9781119959946.ch20 · Cited by 52
Self-citationExacerbation of Recurrent Depression as a Result of Treatment With Varenicline
Popkin, M. K. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111735 · Cited by 50 · cited 1×
“These include exacerbation of depression in a patient with history of recurrent major depressive disorder, previously stable on fluoxetine;([13]) psychotic relapse in a patient with schizophrenia;([14]) a manic episode in a patient with a history of bipolar disorder, previously stable on valproic acid;([15])”
Background
Cited by
Pharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433
Interventions for smoking cessation and reduction in individuals with schizophrenia
Tsoi, D. T., Porwal, M., & Webster, A. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007253.pub3 · Cited by 304
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub6 · Cited by 177
Metadata
- Authors
- Kasliwal, R., Wilton, L. V., & Shakir, S. A. W.
- Affiliations
- Drug Safety Research Unit (GB)
- Corresponding author
- Kasliwal, Rachna
- ORCID
- Shakir, Saad A.W.
- Venue
- Drug Safety
- Published
- 2009-05
- Volume
- 32
- Issue
- 6
- Pages
- 499-507
- ISSN
- 0114-5916 (ISSN-L)
- OpenAlex
- W187469247
- Cited by
- 71
- References
- 6
- Citations by year
- 2024: 1 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 7 · 2015: 3 · 2014: 4 · 2013: 9 · 2012: 6
- FWCI
- 14.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Portsmouth
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- varenicline, smoking cessation, post-marketing safety, adverse drug reactions, psychiatric adverse events, depression, suicidal ideation, medication use, prescription-event monitoring, general practice, nicotine receptor partial agonist, nausea and vomiting, drug discontinuation, England, United Kingdom, pharmacoepidemiology, sleep disorders, mood changes
- MeSH terms
- Varenicline, Adult, Benzazepines, Drug Utilization, England, Family Practice, Female, Humans, Male, Middle Aged, Drug Prescriptions, Quinoxalines, Safety, Smoking Cessation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Drug Utilization Profile of Varenicline as Used in General Practice in England: Interim Results from a Prescription-Event Monitoring Study. https://app.cochat.ai/papers/10.2165/00002018-200932060-00006
- The paper
- Kasliwal, R., Wilton, L. V., & Shakir, S. A. W. (2009). Safety and Drug Utilization Profile of Varenicline as Used in General Practice in England: Interim Results from a Prescription-Event Monitoring Study. Drug Safety. https://doi.org/10.2165/00002018-200932060-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.